The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Cancer
Autores principales: Ross, Jeffrey S., Wang, Kai, Chmielecki, Juliann, Gay, Laurie, Johnson, Adrienne, Chudnovsky, Jacob, Yelensky, Roman, Lipson, Doron, Ali, Siraj M, Elvin, Julia A., Vergilio, Jo‐Anne, Roels, Steven, Miller, Vincent A, Nakamura, Brooke N., Gray, Adam, Wong, Michael K, Stephens, Philip J
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Genetics and Epigenetics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5049644/
https://ncbi.nlm.nih.gov/pubmed/26314551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29825
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares